KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Current Deferred Revenue (2016 - 2025)

CRISPR Therapeutics AG's Current Deferred Revenue history spans 9 years, with the latest figure at $15.8 million for Q4 2025.

  • For Q4 2025, Current Deferred Revenue rose 310.17% year-over-year to $15.8 million; the TTM value through Dec 2025 reached $15.8 million, up 310.17%, while the annual FY2025 figure was $15.8 million, 310.17% up from the prior year.
  • Current Deferred Revenue for Q4 2025 was $15.8 million at CRISPR Therapeutics AG, up from $1.3 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $15.8 million in Q4 2025 and bottomed at $1.0 million in Q4 2021.
  • The 4-year median for Current Deferred Revenue is $3.3 million (2023), against an average of $3.8 million.
  • The largest annual shift saw Current Deferred Revenue tumbled 91.71% in 2021 before it soared 310.17% in 2025.
  • A 4-year view of Current Deferred Revenue shows it stood at $1.0 million in 2021, then soared by 306.03% to $4.1 million in 2023, then dropped by 6.33% to $3.8 million in 2024, then skyrocketed by 310.17% to $15.8 million in 2025.
  • Per Business Quant, the three most recent readings for CRSP's Current Deferred Revenue are $15.8 million (Q4 2025), $1.3 million (Q3 2025), and $2.1 million (Q2 2025).